DOJ watchdog says DEA medical-registration controls leave gaps
A Justice Department watchdog found that the Drug Enforcement Administration’s system for registering medical practitioners who handle controlled substances lacked several routine safeguards, including standardized quality checks and regular investigations of the agency’s largest registrant group.
The findings were published July 9, 2026, in DOJ Inspector General Audit Report 26-069. The review generally covered October 2021 through August 2025, with much of its data drawn from fiscal years 2022 through 2024.
The audit does not say that most doctors or other practitioners were violating federal law. It identifies weaknesses in the DEA’s oversight process and risks that those weaknesses could make problems harder to detect. The audit also said its testing found nothing that caused the OIG to believe the DEA was out of compliance with the specific laws and regulations examined.
Millions of applications, limited secondary review
A DEA registration is the federal authorization required for health professionals licensed to prescribe, dispense or administer controlled substances. The registration system is therefore one part of the federal government’s effort to track controlled substances through the supply chain.
The DEA received more than 2.1 million initial and renewal applications from medical practitioners during fiscal years 2022 through 2024, according to the audit.
About 1.5 million renewal applications were described by the OIG as auto-approved by the system without secondary review from a registration specialist or diversion investigator. The DEA objected to that terminology, saying its Controlled Substances Act online renewal process is structured and system-assisted, not instantaneous or wholly automatic.
The OIG responded that it used “auto-approved” and related terms based on terminology found in DEA documentation and said its description was consistent with the evidence it reviewed.
Regardless of the terminology, the watchdog said the DEA lacked a standardized quality-assurance program for the registration process. Local supervisors could decide whether to conduct internal checks, leaving no uniform national method for testing the accuracy and consistency of registration work.
Practitioners were not in the routine investigation plan
The audit also found that the DEA did not specify medical-practitioner investigations in its annual scheduled-investigation workplan, even though practitioners make up the largest group of registrants.
As of April 2025, fewer than 700 diversion investigators were responsible for more than 1.9 million medical practitioners, the report said. A DEA official told the OIG that investigations of practitioners generally arose from complaints from patients, staff, pharmacists or employers, as well as tips from the public.
That staffing comparison does not establish that individual practitioners were unqualified or that patients were harmed. It shows the scale of the oversight challenge and why the OIG questioned whether the DEA had adequately assessed the share of practitioners receiving routine attention.
Training verification relied on attestations
The audit examined the DEA’s handling of the one-time eight-hour training requirement created by the Medication Access and Training Expansion Act, commonly known as the MATE Act. The requirement took effect in June 2023 and generally applies to DEA-registered medical practitioners other than veterinarians.
Applicants must attest on the online registration form that they have met the training requirement. The OIG said the DEA generally did not collect supporting documentation or other evidence, except when such material was requested during an investigation. The watchdog said that limited the agency’s ability to independently verify compliance unless an investigation began.
The report reviewed a judgmental, non-statistical sample of 300 active practitioner records, with 30 practitioners selected from each of 10 states. The OIG said the sample was not statistically representative and that its results could not be projected to the full registrant population.
In that sample, the OIG found that 297 practitioners had active state licenses and three held DEA registrations associated with expired state licenses. The audit also identified eight records with arrests or medical probationary periods and said six of those cases had not been referred for further review as required. The OIG recommended that the DEA examine those six records.
DEA agreed to recommendations, but follow-up remains open
The DEA agreed with all five recommendations. The agency said it reviewed the six registrants identified by the OIG in February 2026 and found no adverse actions related to their handling of controlled substances. The DEA said it would provide supporting documentation.
The DEA also said it incorporated medical practitioners into its fiscal 2026 scheduled-investigation workplan and assessed the resources needed for that work. The OIG reviewed the workplan documentation and confirmed that each diversion group would review some medical-practitioner registrants.
But the OIG said the DEA had not documented how it determined that the number of practitioner reviews was a practical percentage of the annual workplan or how it calculated the resources needed. The OIG therefore treated the recommendation as resolved but said it could not be closed until that documentation is provided.
The same distinction applies to the other recommendations. The OIG considers the report resolved because the DEA concurred and described corrective actions, but closure still requires evidence that standardized quality controls were implemented, the renewal process received a comprehensive risk assessment, staffing gaps were addressed or a strategy was developed, and the six-record review was fully documented.
The public report is partially redacted because it contains law-enforcement-sensitive information.
What the audit means for patients
The audit alone does not show that a particular doctor is unqualified or that a prescription is unlawful. It also does not establish widespread illegal prescribing, diversion or patient harm.
Its practical message is narrower: the DEA’s national registration system did not provide the level of routine verification and quality assurance the watchdog expected. The remaining question is whether the agency’s corrective steps will be implemented effectively and supported with enough staff and documentation.
Patients or families with concerns about prescribing or licensing should direct them to the relevant state medical board, pharmacist, employer or DEA reporting channel rather than infer misconduct from the audit alone.
Sources
Discover more from Interactive News
Subscribe to get the latest posts sent to your email.
